Global TIL Therapies Market : Distribution by Target Indication, Key Players and Key Geographical Regions: Industry Trends and Global Forecasts, 2023-2035

Table of Contents

1. PREFACE
1.1. Introduction
1.2. Key Market Insights
1.3. Scope of the Report
1.4. Research Methodology
1.5. Key Questions Answered
1.6. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Pillars of Cancer Therapy
3.3. Overview of Immunotherapies
3.4. Fundamentals of Cancer Immunotherapy
3.5. Classification of Cancer Immunotherapies
3.5.1. By Mechanism of Action
3.5.2. By Type of Target
3.5.3. By Approach
3.5.4. By Product Class
3.6. T-Cell Immunotherapies
3.6.1. Historical Evolution
3.6.2. Key Considerations for Developing T-Cell Immunotherapies
3.6.3. Strategies Employed for the Redirection of T-Cells
3.6.4. Manufacturing of Engineered T-Cells
3.6.5. T-Cell Transduction and Transfection Methods
3.7. Tumor Infiltrating Lymphocyte (TIL)-based Cell Therapy
3.7.1. Development History
3.7.2. Development of TILs Therapy
3.8. Key Benefits and Roadblocks
3.9. Concluding Remarks

4. TIL-BASED THERAPIES: MARKET LANDSCAPE
4.1. Chapter Overview
4.2. TIL-based Therapies: Overall Market Landscape
4.2.1. Analysis by Type of Developer
4.2.2. Analysis by Phase of Development
4.2.3. Analysis by Therapeutic Area
4.2.4. Analysis by Key Target Indications
4.2.5. Analysis by Source of T-Cells
4.2.6. Analysis by Route of Administration
4.2.7. Analysis by Dosing Frequency
4.2.8. Analysis by Target Patient Segment
4.2.9. Analysis by Type of Therapy
4.2.10. Most Active Industry Players: Analysis by Number of TIL-based Therapies
4.2.11. Most Active Non-Industry Players: Analysis by Number of TIL-based Therapies
4.3. TIL-based Therapies: Overall Developer Landscape
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Location of Headquarters

5. CLINICAL TRIAL ANALYSIS
5.1. Chapter Overview
5.2. Scope and Methodology
5.3. TIL-based Therapies: Clinical Trial Analysis
5.3.1. Analysis by Trial Registration Year
5.3.2. Analysis by Trial Registration Year and Enrolled Patient Population
5.3.3. Analysis by Trial Status
5.3.4. Analysis by Trial Registration Year and Trial Status
5.3.5. Analysis by Trial Phase
5.3.6. Analysis by Trial Phase and Enrolled Patient Population
5.3.7. Analysis by Target Patient Segment
5.3.8. Analysis by Type of Sponsor / Collaborator
5.3.9. Analysis by Study Design
5.3.10. Most Active Industry Players: Analysis by Number of Registered Trials
5.3.11. Most Active Non-Industry Players: Analysis by Number of Registered Trials
5.3.12. Word Cloud Analysis: Emerging Focus Areas
5.3.13. Analysis of Clinical Trials by Geography
5.3.14. Analysis of Enrolled Patient Population by Geography

6. KEY OPINION LEADERS
6.1. Chapter Overview
6.2. Assumptions and Key Parameters
6.3. Methodology
6.4. TIL-based Therapies: Key Opinion Leaders
6.4.1. Analysis by Type of Organization
6.4.2. Analysis by Affiliated Organization
6.4.3. Analysis by Qualification
6.4.4. Analysis by Geographical Location of KOLs
6.4.5. KOL Activeness versus KOL Strength
6.4.6. Most Prominent KOLs: Analysis by RA score
6.4.7. Most Prominent KOLs: Comparison of RA Score and Third-Party Score

7. TIL-BASED THERAPY PROFILES
7.1. Chapter Overview
7.2. LN-144 / Lifileucel (Iovance Biotherapeutics)
7.2.1. Therapy Overview
7.2.2. Clinical Trial Information
7.2.3. Clinical Trial Endpoints
7.2.4. Clinical Trial Results
7.2.5. Estimated Sales Revenues
7.3. LN-145 (Iovance Biotherapeutics)
7.3.1. Therapy Overview
7.3.2. Clinical Trial Information
7.3.3. Clinical Trial Endpoints
7.3.4. Clinical Trial Results
7.3.5. Estimated Sales Revenues
7.4. ITIL-168 (Instil Bio)
7.4.1. Therapy Overview
7.4.2. Clinical Trial Information
7.4.3. Clinical Trial Endpoints
7.4.4. Clinical Trial Results
7.4.5. Estimated Sales Revenues
7.5. LTX-315 (Lytix Biopharma)
7.5.1. Therapy Overview
7.5.2. Clinical Trial Information
7.5.3. Clinical Trial Endpoints
7.5.4. Clinical Trial Results
7.5.5. Estimated Sales Revenues

8. PARTNERSHIPS AND COLLABORATIONS
8.1. Chapter Overview
8.2. Partnership Models
8.3. TIL-based Therapies: Partnerships and Collaborations
8.3.1. Analysis by Year of Partnership
8.3.2. Analysis by Type of Partnership
8.3.3. Analysis by Year of Partnership and Type of Partnership
8.3.4. Analysis by Type of Partner
8.3.5. Most Popular Products: Analysis by Number of Partnerships
8.3.6. Most Active Industry Players: Analysis by Number of Partnerships
8.3.7. Most Active Non-Industry Players: Analysis by Number of Partnerships
8.3.8. Analysis by Geography
8.3.8.1. Intercontinental and Intracontinental Agreements
8.3.8.2. International and Local Deals

9. FUNDING AND INVESTMENT ANALYSIS
9.1. Chapter Overview
9.2. Type of Funding
9.3. TIL-based Therapies: Funding and Investment Analysis
9.3.1. Analysis by Year of Investment
9.3.2. Analysis by Amount Invested
9.3.3. Analysis by Type of Funding
9.3.4. Analysis by Type of Investor
9.3.5. Most Active Players: Analysis by Number of Instances
9.3.6. Most Active Investors: Analysis by Amount Invested
9.3.7. Analysis of Amount Invested by Geography
9.3.8. Most Active Investors: Analysis by Number of Funding Instances

10. PATENT ANALYSIS
10.1. Chapter Overview
10.2. Scope and Methodology
10.3. TIL-based Therapies: Patent Analysis
10.3.1. Analysis by Patent Publication Year
10.3.2. Analysis By Patent Application Year
10.3.3. Analysis by Geography
10.3.4. Analysis by Type of Player
10.3.5. Analysis by CPC Symbols
10.3.6. Word Cloud Analysis: Emerging Focus Areas
10.3.7. Leading Players: Analysis by Number of Patents
10.3.8. TIL-based Therapies: Patent Benchmarking
10.3.9. Analysis By Patent Characteristics
10.3.10. TIL-based Therapies: Patent Valuation

11. CASE STUDY: CELL THERAPY MANUFACTURING
11.1. Chapter Overview
11.2. Overview of Cell Therapy Manufacturing
11.3. Cell Therapy Manufacturing Models
11.3.1. Centralized Manufacturing Model
11.3.2. Decentralized Manufacturing Model
11.4. Scalability of Cell Therapy Manufacturing Processes
11.4.1. Scale-Up
11.4.2. Scale-Out
11.5. Types of Cell Therapy Manufacturers
11.6. Key Challenges Related to Manufacturing of Cell Therapies
11.7. Important Factors for Cell Therapy Manufacturing
11.7.1. Characterization
11.7.2. Cost of Goods
11.8. Automation of Cell Therapy Manufacturing Process
11.9. Cell Therapy Manufacturing Supply Chain
11.10. Comparison of Player Having In-House Capabilities and Contract Manufacturers
11.11. Regulatory Landscape
11.12. Future Perspectives

12. COST PRICE ANALYSIS
12.1. Chapter Overview
12.2. Factors Contributing to the High Price of Cell / Gene Therapies
12.3. Pricing Models for T-Cell Immunotherapies
12.3.1. Based on Associated Costs
12.3.2. Based on Availability of Competing Products
12.3.3. Based on Patient Segment
12.3.4. Based on Opinions of Industry Experts
12.4. Reimbursement related Considerations for T-Cell Immunotherapies

13. MARKET FORECAST AND OPPORTUNITY ANALYSIS
13.1. Chapter Overview
13.2. Scope and Limitations
13.3. Key Assumptions and Forecast Methodology
13.4. Global TIL-Based Therapies Market, 2022-2035
13.4.1. TIL-based Therapies Market: Analysis by Target Indication
13.4.2. TIL-based Therapies Market: Analysis by Key Players
13.4.3. TIL-based Therapies Market: Analysis by Key Geographical Regions
13.4.4. Product Wise Sales Forecast
13.4.4.1. Lifileucel / LN-144 (Iovance Biotherapeutics)
13.4.4.1.1. Sales Forecast (USD Million)
13.4.4.1.2. Net Present Value (USD Million)
13.4.4.1.3. Value Creation Analysis
13.4.4.2. LN-145 (Iovance Biotherapeutics)
13.4.4.2.1. Sales Forecast (USD Million)
13.4.4.2.2. Net Present Value (USD Million)
13.4.4.2.3. Value Creation Analysis
13.4.4.3. LTX-315 and TILs (Lytix Biopharma)
13.4.4.3.1. Sales Forecast (USD Million)
13.4.4.3.2. Net Present Value (USD Million)
13.4.4.3.3. Value Creation Analysis
13.4.4.4. TILs (Prometheus Laboratories)
13.4.4.4.1. Sales Forecast (USD Million)
13.4.4.4.2. Net Present Value (USD Million)
13.4.4.4.3. Value Creation Analysis
13.4.4.5. Donor Lymphocyte Infusion (Incyte)
13.4.4.5.1. Sales Forecast (USD Million)
13.4.4.5.2. Net Present Value (USD Million)
13.4.4.5.3. Value Creation Analysis
13.4.4.6. ITIL-168 (Instil Bio)
13.4.4.6.1. Sales Forecast (USD Million)
13.4.4.6.2. Net Present Value (USD Million)
13.4.4.6.3. Value Creation Analysis
13.4.4.7. IOV-2001 (Iovance Biotherapeutics)
13.4.4.7.1. Sales Forecast (USD Million)
13.4.4.7.2. Net Present Value (USD Million)
13.4.4.7.3. Value Creation Analysis
13.4.4.8. TILs (CAR-T (Shanghai) Cell Biotechnology)
13.4.4.8.1. Sales Forecast (USD Million)
13.4.4.8.2. Net Present Value (USD Million)
13.4.4.8.3. Value Creation Analysis
13.4.4.9. TILs (Bristol-Myers Squibb)
13.4.4.9.1. Sales Forecast (USD Million)
13.4.4.9.2. Net Present Value (USD Million)
13.4.4.9.3. Value Creation Analysis

14. COMPANY PROFILES
14.1. Chapter Overview
14.2. Cellectis
14.3. Cellular Biomedicine Group
14.4. Iovance Biotherapeutics
14.5. Lytix Biopharma
14.6. Phio Pharmaceuticals

15. CONCLUDING REMARKS

16. EXECUTIVE INSIGHTS

17. APPENDIX I: TABULATED DATA

18. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures
Figure 2.1 Executive Summary: Overall Market Landscape
Figure 2.2 Executive Summary: Clinical Trial Analysis
Figure 2.3 Executive Summary: Partnerships and Collaborations
Figure 2.4 Executive Summary: Funding and Investment Analysis
Figure 2.5 Executive Summary: Patent Analysis
Figure 2.6 Executive Summary: Market Forecast and Opportunity Analysis
Figure 3.1 Pillars of Cancer Therapy
Figure 3.2 Differences between Active and Passive Immunotherapies
Figure 3.3 Differences between Specific and Non-Specific Immunotherapies
Figure 3.4 Strategies Employed for the Redirection of T-Cells
Figure 3.5 T-Cell Manufacturing: General Procedure
Figure 3.6 TIL-based Therapies: Development Process
Figure 4.1 TIL-based Therapies: Distribution by Type of Developer
Figure 4.2 TIL-based Therapies: Distribution by Phase of Development
Figure 4.3 TIL-based Therapies: Distribution by Therapeutic Area
Figure 4.4 TIL-based Therapies: Distribution by Key Target Indications
Figure 4.5 TIL-based Therapies: Distribution by Source of T-Cells
Figure 4.6 TIL-based Therapies: Distribution by Route of Administration
Figure 4.7 TIL-based Therapies: Distribution by Dosing Frequency
Figure 4.8 TIL-based Therapies: Distribution by Target Patient Segment
Figure 4.9 TIL-based Therapies: Distribution by Type of Therapy
Figure 4.10 Most Active Industry Players: Distribution by Number of TIL-based Therapies
Figure 4.11 Most Active Non-Industry Players: Distribution by Number of TIL-based Therapies
Figure 4.12 TIL-based Therapy Developers: Distribution by Year of Establishment
Figure 4.13 TIL-based Therapy Developers: Distribution by Company Size
Figure 4.14 TIL-based Therapy Developers: Distribution by Location of Headquarters (Region-wise)
Figure 4.15 TIL-based Therapy Developers: Distribution by Location of Headquarters (Country-wise)
Figure 5.1 Clinical Trial Analysis: Scope and Methodology
Figure 5.2 Clinical Trial Analysis: Cumulative Distribution of Trials by Trial Registration Year, Pre-2017-2022
Figure 5.3 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Registration Year, Pre-2017-2022
Figure 5.4 Clinical Trial Analysis: Distribution by Trial Status
Figure 5.5 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status, Pre-2017-2022
Figure 5.6 Clinical Trial Analysis: Distribution of Trials by Trial Phase
Figure 5.7 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase
Figure 5.8 Clinical Trial Analysis: Distribution by Target Patient Segment
Figure 5.9 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 5.10 Clinical Trial Analysis: Distribution by Study Design
Figure 5.11 Most Active Industry Players: Distribution by Number of Registered Trials
Figure 5.12 Most Active Non-Industry Players: Distribution by Number of Registered Trials
Figure 5.13 Word Cloud Analysis: Emerging Focus Areas
Figure 5.14 Clinical Trial Analysis: Distribution of Trials by Geography
Figure 5.15 Clinical Trial Analysis: Distribution of Completed Clinical Trials by Geography
Figure 5.16 Clinical Trial Analysis: Distribution of Active Clinical Trials by Geography
Figure 5.17 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Geography
Figure 6.1 KOL Analysis: Distribution by Type of Organization
Figure 6.2 KOL Analysis: Distribution by Affiliated Organization
Figure 6.3 KOL Analysis: Distribution by Qualification
Figure 6.4 KOL Analysis: Distribution by Geography
Figure 6.5 TIL-based Therapies Scatter Plot: KOL Activeness versus KOL Strength
Figure 6.6 Most Prominent KOLs: KOL Activeness versus KOL Strength
Figure 6.7 Most Prominent KOLs: Distribution by RA Score
Figure 6.8 Most Prominent KOLs: Comparison of RA Score with Third-Party Score
Figure 6.9 Most Prominent KOLs: Comparison of RA Score with Third-Party Score (Scatter Plot)
Figure 7.1 LN-144: Estimated Sales Revenues
Figure 7.2 LN-145: Estimated Sales Revenues
Figure 7.3 ITIL-168: Estimated Sales Revenues
Figure 7.4 LTX-315: Estimated Sales Revenues
Figure 8.1 Partnerships and Collaborations: Cumulative Year-Wise Trend, Pre-2015-2022
Figure 8.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 8.3 Partnerships and Collaborations: Distribution by Type of Partnership, Pre-2015 and Post-2015
Figure 8.4 Partnerships and Collaborations: Distribution by Year and Type of Partnership, Pre-2015-2022
Figure 8.5 Partnerships and Collaborations: Distribution by Type of Partner
Figure 8.6 Partnerships and Collaborations: Year-Wise Distribution by Type of Partner, Pre-2015-2022
Figure 8.7 Most Popular Products: Distribution by Number of Partnerships
Figure 8.8 Most Active Industry Players: Distribution by Number of Partnerships
Figure 8.9 Most Active Non-Industry Players: Distribution by Number of Partnerships
Figure 8.10 Partnerships and Collaborations: Intercontinental and Intracontinental Deals
Figure 8.11 Partnerships and Collaborations: International and Local Deals
Figure 9.1 Funding and Investment Analysis: Cumulative Year-wise Distribution of Instances, Pre-2018-2022
Figure 9.2 Funding and Investment Analysis: Cumulative Year-wise Distribution of Amount Invested, Pre-2018-2022 (USD Million)
Figure 9.3 Funding and Investment Analysis: Distribution of Instances by Type of Funding
Figure 9.4 Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding (USD Million)
Figure 9.5 Funding and Investment Analysis: Distribution by Type of Investor
Figure 9.6 Funding and Investment Analysis: Distribution of Amount Invested by Type of Investor (USD Million)
Figure 9.7 Most Active Players: Distribution by Number of Instances
Figure 9.8 Most Active Players: Distribution by Amount Invested (USD Million)
Figure 9.9 Funding and Investment Analysis: Distribution of Amount Invested by Geography
Figure 10.1 Patent Analysis: Distribution by Type of Patent
Figure 10.2 Patent Analysis: Cumulative Distribution by Patent Publication Year
Figure 10.3 Patent Analysis: Cumulative Distribution by Patent Application Year
Figure 10.4 Patent Analysis: Cumulative Year-wise Distribution of Granted Patents
Figure 10.5 Patent Analysis: Cumulative Year-wise Distribution of Filed Patent Applications
Figure 10.6 Patent Analysis: Year-wise Distribution of Filed Patent Applications and Granted Patents
Figure 10.7 Patent Analysis: Distribution by Geography
Figure 10.8 Patent Analysis: Distribution by Type of Player
Figure 10.9 Patent Analysis: Distribution by CPC Symbols
Figure 10.10 Word Cloud Analysis: Emerging Focus Areas
Figure 10.11 Leading Industry Players: Distribution by Number of Patents
Figure 10.12 Leading Non-Industry Players: Distribution by Number of Patents
Figure 10.13 Leading Patent Assignees: Distribution by Number of Patents
Figure 10.14 Leading Players: Benchmarking by Patent Characteristics (CPC Symbols)
Figure 10.15 Patent Analysis: Distribution by Patent Age
Figure 10.16 TIL-based Cell Therapies: Patent Valuation Analysis
Figure 11.1 Steps for Manufacturing Cell Therapies
Figure 11.2 Centralized Manufacturing: Process Model
Figure 11.3 Decentralized Manufacturing: Process Model
Figure 11.4 Cell Therapy Manufacturing: Types of Manufacturers
Figure 11.5 Cell Therapy: Challenges and Drivers
Figure 11.6 Cell Therapies: Potency as Critical Quality Attribute
Figure 11.7 Cell Therapy Manufacturing: Supply Chain Model
Figure 11.8 Cell Therapy Manufacturing: Supply Chain Risk Assessment Considerations
Figure 12.1 Approved T-Cell Therapies: Pricing Model based on Patient Segment
Figure 13.1 Global TIL-based Therapies Market, 2022-2035 (USD Billion)
Figure 13.2 TIL-based Therapies Market: Distribution by Target Indication, 2025 and 2035 (USD Billion)
Figure 13.3 TIL-based Therapies Market: Distribution by Key Players, 2025 and 2035 (USD Billion)
Figure 13.4 TIL-based Therapies Market: Distribution by Geography, 2025 and 2035 (USD Billion)
Figure 13.5 Lifileucel / LN-144 (Iovance Biotherapeutics) Sales Forecast, till 2035 (USD Million)
Figure 13.6 LN-145 (Iovance Biotherapeutics) Sales Forecast, till 2035 (USD Million)
Figure 13.7 LTX-315 and TILs (Lytix Biopharma) Sales Forecast, till 2035 (USD Million)
Figure 13.8 TILs (Prometheus Laboratories) Sales Forecast, till 2035 (USD Million)
Figure 13.9 Donor Lymphocyte Infusion (Incyte) Sales Forecast, till 2035 (USD Million)
Figure 13.10 ITIL-168 (Instil Bio) Sales Forecast, till 2035 (USD Million)
Figure 13.11 IOV-2001 (Iovance Biotherapeutics) Sales Forecast, till 2035 (USD Million)
Figure 13.12 TILs (CAR-T (Shanghai) Cell Biotechnology) Sales Forecast, till 2035 (USD Million)
Figure 13.13 TILs (Bristol-Myers Squibb) Sales Forecast, till 2035 (USD Million)
Figure 15.1 Concluding Remarks: Market Landscape
Figure 15.2 Concluding Remarks: Clinical Trial Analysis
Figure 15.3 Concluding Remarks: Key Opinion Leaders
Figure 15.4 Concluding Remarks: Partnerships & Collaborations
Figure 15.5 Concluding Remarks: Funding and Investment Analysis
Figure 15.6 Concluding Remarks: Patent Analysis
Figure 15.7 Concluding Remarks: Market Forecast

List Of Tables
Table 3.1 Types of Immunotherapies and Affiliated Mechanisms of Action
Table 3.2 FDA Approved Antibody-based Cancer Therapeutics
Table 3.3 Retroviral Vectors: Salient Features
Table 3.4 Lentiviral Vectors: Salient Features
Table 4.1 TIL-based Therapies: Clinical Pipeline
Table 4.2 TIL-based Therapies: Information on Route of Administration, Source of T-Cells, Dosing Frequency, Target Patient Segment and Type of Therapy
Table 4.3 TIL-based Therapies: Preclinical Pipeline
Table 4.4 List of TIL-based Developers
Table 6.1 TIL-based Therapies: List of Principal Investigators
Table 7.1 TIL Cell Therapies: List of Therapies Profiled
Table 7.2 Therapy Profile: LN-144 (Iovance Biotherapeutics)
Table 7.3 LN-144: Clinical Trial Information
Table 7.4 LN-144: Clinical Trial Endpoints
Table 7.5 LN-144: Clinical Trial Results
Table 7.6 Therapy Profile: LN-145 (Iovance Biotherapeutics)
Table 7.7 LN-145: Clinical Trial Information
Table 7.8 LN-145: Clinical Trial Endpoints
Table 7.9 LN-145: Clinical Trial Results
Table 7.10 Therapy Profile: ITIL-168 (Instil Bio)
Table 7.11 ITIL-168: Clinical Trial Information
Table 7.12 ITIL-168: Clinical Trial Endpoints
Table 7.13 ITIL-168: Clinical Trial Results
Table 7.14 Therapy Profile: LTX-315 (Lytix Biopharma)
Table 7.15 LTX-315: Clinical Trial Information
Table 7.16 LTX-315: Clinical Trial Endpoints
Table 7.17 LTX-315: Clinical Trial Results
Table 8.1 List of Partnerships and Collaborations, 2005-2022
Table 9.1 List of Funding and Investments, 2007-2022
Table 9.2 Funding and Investment Analysis: Summary of Investments
Table 10.1 Patent Analysis: Prominent CPC Symbols
Table 10.2 Patent Analysis: Most Popular CPC Symbols
Table 10.3 Patent Analysis: List of Top CPC Symbols
Table 10.4 Patent Analysis: Summary of Benchmarking Analysis
Table 10.5 Patent Analysis: Categorization based on Weighted Valuation Scores
Table 11.1 Assessment Strategies for Different Manufacturing Processes
Table 11.2 Advantages and Disadvantages of Centralized and Decentralized Manufacturing Models
Table 11.3 Cell Therapy Manufacturing: Companies with In-House Capabilities and Contract Manufacturers
Table 12.1 Price of Marketed Gene / Cell Therapies
Table 12.2 Price of Marketed Targeted Drugs
Table 12.3 TIL-based Therapies: Expert Opinions on Pricing
Table 12.4 TIL-based Therapies: Reimbursement Landscape
Table 13.1 TIL-based Therapies: List of Forecasted Molecules
Table 13.2 Lifileucel / LN-144 (Iovance Biotherapeutics): Net Present Value (USD Million)
Table 13.3 Lifileucel / LN-144 (Iovance Biotherapeutics): Value Creation Analysis (USD Million)
Table 13.4 LN-145 (Iovance Biotherapeutics): Net Present Value (USD Million)
Table 13.5 LN-145 (Iovance Biotherapeutics): Value Creation Analysis (USD Million)
Table 13.6 LTX-315 and TILs (Lytix Biopharma): Net Present Value (USD Million)
Table 13.7 LTX-315 and TILs (Lytix Biopharma): Value Creation Analysis (USD Million)
Table 13.8 TILs (Prometheus Laboratories): Net Present Value (USD Million)
Table 13.9 TILs (Prometheus Laboratories): Value Creation Analysis (USD Million)
Table 13.10 Donor Lymphocyte Infusion (Incyte): Net Present Value (USD Million)
Table 13.11 Donor Lymphocyte Infusion (Incyte): Value Creation Analysis (USD Million)
Table 13.12 ITIL-168 (Instil Bio): Net Present Value (USD Million)
Table 13.13 ITIL-168 (Instil Bio): Value Creation Analysis (USD Million)
Table 13.14 IOV-2001 (Iovance Biotherapeutics): Net Present Value (USD Million)
Table 13.15 IOV-2001 (Iovance Biotherapeutics): Value Creation Analysis (USD Million)
Table 13.16 TILs (CAR-T (Shanghai) Cell Biotechnology): Net Present Value (USD Million)
Table 13.17 TILs (CAR-T (Shanghai) Cell Biotechnology): Value Creation Analysis (USD Million)
Table 13.18 TILs (Bristol-Myers Squibb): Net Present Value (USD Million)
Table 13.19 TILs (Bristol-Myers Squibb): Value Creation Analysis (USD Million)
Table 14.1 Leading TIL-based Therapy Developers
Table 14.2 Cellectis: Company Profile
Table 14.3 Cellular Biomedicine Group: Company Profile
Table 14.4 Iovance Biotherapeutics: Company Profile
Table 14.5 Lytix Biopharma: Company Profile
Table 14.6 Phio Pharmaceuticals: Company Profile
Table 17.1 TIL-based Therapies: Distribution by Type of Developer
Table 17.2 TIL-based Therapies: Distribution by Phase of Development
Table 17.3 TIL-based Therapies: Distribution by Therapeutic Area
Table 17.4 TIL-based Therapies: Distribution by Key Target Indications
Table 17.5 TIL-based Therapies: Distribution by Source of T-Cells
Table 17.6 TIL-based Therapies: Distribution by Route of Administration
Table 17.7 TIL-based Therapies: Distribution by Dosing Frequency
Table 17.8 TIL-based Therapies: Distribution by Target Patient Segment
Table 17.9 TIL-based Therapies: Distribution by Type of Therapy
Table 17.10 Most Active Industry Players: Analysis by Number of TIL-based Therapies
Table 17.11 Most Active Non-Industry Players: Distribution by Number of TIL-based Therapies
Table 17.12 TIL-based Therapy Developers: Distribution by Year of Establishment
Table 17.13 TIL-based Therapy Developers: Distribution by Company Size
Table 17.14 TIL-based Therapy Developers: Distribution by Location of Headquarters (Region-wise)
Table 17.15 TIL-based Therapy Developers: Distribution by Location of Headquarters (Country-wise)
Table 17.16 Clinical Trial Analysis: Cumulative Distribution of Trials by Trial Registration Year, Pre-2017-2022
Table 17.17 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Registration Year, Pre-2017-2022
Table 17.18 Clinical Trial Analysis: Distribution by Trial Status
Table 17.19 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status, Pre-2013-2022
Table 17.20 Clinical Trial Analysis: Distribution of Trials by Trial Phase
Table 17.21 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase
Table 17.22 Clinical Trial Analysis: Distribution by Target Patient Segment
Table 17.23 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 17.24 Clinical Trial Analysis: Distribution by Study Design
Table 17.25 Most Active Industry Players: Distribution by Number of Registered Trials
Table 17.26 Most Active Non-Industry Players: Distribution by Number of Registered Trials
Table 17.27 Clinical Trial Analysis: Distribution of Trials by Geography
Table 17.28 Clinical Trial Analysis: Distribution of Completed Clinical Trials by Geography
Table 17.29 Clinical Trial Analysis: Distribution of Active Clinical Trials by Geography
Table 17.30 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Geography
Table 17.31 KOL Analysis: Distribution by Type of Organization
Table 17.32 KOL Analysis: Distribution by Affiliated Organization
Table 17.33 KOL Analysis: Distribution by Qualification
Table 17.34 KOL Analysis: Distribution by Geography
Table 17.35 Most Prominent KOLs: Distribution by RA Score
Table 17.36 Most Prominent KOLs: Comparison of RA Score with Third-Party Score
Table 17.37 LN-144: Estimated Sales Revenues
Table 17.38 LN-145: Estimated Sales Revenues
Table 17.39 ITIL-168: Estimated Sales Revenues
Table 17.40 LTX-315: Estimated Sales Revenues
Table 17.41 Partnerships and Collaborations: Cumulative Year-Wise Trend, Pre-2015-2022
Table 17.42 Partnerships and Collaborations: Distribution by Type of Partnership
Table 17.43 Partnerships and Collaborations: Distribution by Type of Partnership, Pre-2015 and Post-2015
Table 17.44 Partnerships and Collaborations: Distribution by Type of Partner
Table 17.45 Partnerships and Collaborations: Year-Wise Distribution by Type of Partner, Pre-2015-2022
Table 17.46 Most Popular Products: Distribution by Number of Partnerships
Table 17.47 Most Active Industry Players: Distribution by Number of Partnerships
Table 17.48 Most Active Non-Industry Players: Distribution by Number of Partnerships
Table 17.49 Partnerships and Collaborations: Distribution of Intercontinental and Intracontinental Deals
Table 17.50 Partnerships and Collaborations: Distribution of International and Local Deals
Table 17.51 Funding and Investment Analysis: Cumulative Distribution of Instances by Year, Pre-2018-2022
Table 17.52 Funding and Investment Analysis: Cumulative Distribution of Amount Invested by Year, Pre-2018-2022 (USD Million)
Table 17.53 Funding and Investment Analysis: Distribution of Instances by Type of Funding
Table 17.54 Funding and Investment Analysis: Distribution of Total Amount Invested by Type of Funding (USD Million)
Table 17.55 Funding and Investment Analysis: Distribution by Type of Investor
Table 17.56 Funding and Investment Analysis: Distribution of Amount Invested by Type of Investor (USD Million)
Table 17.57 Most Active Players: Distribution by Number of Instances
Table 17.58 Most Active Players: Distribution by Amount Invested (USD Million)
Table 17.59 Funding and Investment Analysis: Distribution of Amount Invested by Geography
Table 17.60 Patent Analysis: Distribution by Type of Patent
Table 17.61 Patent Analysis: Cumulative Distribution by Patent Publication Year
Table 17.62 Patent Analysis: Cumulative Distribution Patent Application Year
Table 17.63 Patent Analysis: Cumulative Distribution by Annual Granted Patents
Table 17.64 Patent Analysis: Cumulative Year-wise Distribution of Filed Patent Applications
Table 17.65 Patent Analysis: Year-wise Distribution of Granted Patents and Patent Applications
Table 17.66 Patent Analysis: Distribution by Geography
Table 17.67 Patent Analysis: Distribution by Type of Player
Table 17.68 Patent Analysis: Distribution by CPC Symbols
Table 17.69 Leading Industry Players: Distribution by Number of Patents
Table 17.70 Leading Non-Industry Players: Distribution by Number of Patents
Table 17.71 Leading Patent Assignees: Distribution by Number of Patents
Table 17.72 Patent Analysis: Distribution by Patent Age
Table 17.73 TIL-based Therapies: Patent Valuation Analysis

• Adelson Medical Research
• A*STAR’s Genome Institute of Singapore
• AbbVie
• AbCellera
• AbCheck
• AbClon
• Abound Bio
• AbVitro
• Abzena
• ACEA Biosciences
• ACROBiosystems
• Adage Capital Partners
• AdAlta
• Adaptimmune Therapeutics
• Adicet Bio
• Adimab
• AgonOx
• Agreen Biotech
• AK (Suzhou) Biomedical
• Aleta Biotherapeutics
• Alexandria Real Estate Equities
• Allogene Therapeutics
• Alpha Biopharma
• Alpine Immune Sciences
• Altor Bioscience
• Amgen
• Anhui Anke Biotechnology
• Anocca
• Antion Biosciences
• Appia Bio
• ARBELE
• Arbor Biotechnologies
• Arcellx
• Astellas Pharma
• Astero Bio
• AstraZeneca
• Asymptote
• Atara Biotherapeutics
• Athenex
• Atreca
• Autolus
• Avalon GloboCare
• Axis Therapeutics
• Baxalta
• Bayer
• Baylor College of Medicine
• Be The Match BioTherapies
• Beam Therapeutics
• Beijing Cancer Hospital
• Beijing Tongren Hospital
• BioAtla
• BioCopy
• BioLife Solutions
• Bionomics
• BioNTech
• Biosceptre
• Blood Centers of America
• bluebird bio
• Boya Jiyin
• Bristol-Myers Squibb
• Cabaletta Bio
• Cabaret Biotech
• Calibr
• California Institute for Regenerative Medicine (CIRM)
• CareDx
• Caribou Biosciences
• Carina Biotech
• CARISMA Therapeutics
• CARsgen Therapeutics
• CAR-T (Shanghai) Cell Biotechnology
• Cartherics
• Casebia Therapeutics
• Celdara Medical
• Celgene
• Cell and Gene Therapy Catapult
• Cell Design Labs
• Cell Medica
• Cellares
• Cellectis
• CELLforCURE
• CellPoint
• Cellular Biomedicine Group
• Cellular Therapeutics
• CellVec
• Celularity
• Celyad
• Center for International Blood and Marrow Transplant Research
• Century Therapeutics
• Children’s Hospital of Philadelphia
• China Regenerative Medicine International (CRMI)
• China (Nanjing) Cell Valley (“CNCV”)
• Chinese PLA General Hospital
• City of Hope Medical Center
• Cognate BioServices
• CoImmune
• Columbia University
• Cormorant Asset Management
• Corondo Biosciences (renamed to Fortress Biotech)
• CRISPR Therapeutics
• Cryoport
• CTM CRC
• CytoLumina Technologies
• Cytovant Sciences
• Cytovia Therapeutics
• DAIICHI SANKYO COMPANY
• Dana-Farber Cancer Institute
• Dartmouth College
• Delenex Therapeutics
• Duke-NUS Medical School
• Editas Medicine
• Eli Lilly
• Elicera Therapeutics
• Endocyte (Acquired by Novartis)
• Etcembly
• Eureka Therapeutics
• Eutilex
• EXUMA Biotech
• Fate Therapeutics
• FetoLumina Technologies
• Fidelity Management & Research
• Five Prime Therapeutics
• Formula Pharmaceuticals
• Fosun Pharmaceutical
• Fraunhofer
• Fred Hutchinson Cancer Research Center
• Fujifilm
• FutureGen Biopharm
• G Plus Life Sciences
• Gadeta
• GC BioPharma
• GE Global Research
• GE Healthcare
• Genentech
• Genezen
• Genmab
• Genocea Biosciences
• GigaGen
• Gilead Sciences
• GlaxoSmithKline
• Glycostem Therapeutics
• GlyTherix
• Gracell Biotechnologies
• Gritstone Oncology
• Guangdong Zhaotai InVivo Biomedicine
• H. Lee Moffitt Cancer Center and Research Institute
• Hadassah Medical Organization
• Harvard University
• HCW Biologics
• Hebei Senlang Biotechnology
• Helmholtz Zentrum
• Henan Cancer Hospital
• Herlev University Hospital
• HiFiBiO Therapeutics
• Hitachi Chemical Advanced Therapeutics Solutions
• Horizon Discovery Group
• Howard Hughes Medical Institute
• IASO Biotherapeutics
• Immatics
• Immetacyte
• ImmunityBio
• ImmunoACT
• Immunocore
• Immunotech Biopharm
• Immunotherapy Foundation
• Imperial Innovations
• Imugene
• Incyte
• Inhibrx
• Instil Bio
• Institut Curie
• Intellia Therapeutics
• Intima Bioscience
• Intrexon
• Iovance Biotherapeutics
• IRICoR
• Janssen
• Jichi Medical University Hospital
• Juno Therapeutics
• JW Therapeutics
• KAEDI
• Karolinska Institute
• KBI Biopharma
• Key Biologics
• Kite Pharma (a Gilead Sciences Company)
• KSQ Therapeutics
• Kuur Therapeutics
• Kyverna Therapeutics
• Laurus Labs
• Legend Biotech
• Leiden University Medical Center
• Leucid Bio
• Leukemia & Lymphoma Society
• Life Technologies
• Lilly Asia Ventures
• Liminatus Pharma
• Lion TCR
• Lonza
• LUMICKS
• Lyell Immunopharma
• Lytix Biopharma
• M.D. Anderson Cancer Center
• MabQuest
• Malin
• Marker Therapeutics
• Massachusetts General Hospital
• MaSTherCell
• Max Delbrück Center for Molecular Medicine 
• MaxCyte
• Mayo Clinic
• MediGene
• MedImmune
• MediTrust Health
• Memorial Sloan Kettering Cancer Center
• Merck
• Mie University Hospital
• Miltenyi Biomedicine
• Miltenyi Biotec
• Minerva Biotechnologies
• Moderna
• MolMed (Acquired by AGC Biologics)
• Mustang Bio
• Myst Therapeutics
• NanoString Technologie
• Nantes University Hospital
• NantKwest
• National Cancer Center Research Institute Japan
• National Cancer Institute
• National Institutes of Health
• National Institutes of Health Clinical Center (CC)
• Neogene Therapeutics
• NeoSTEM
• Nipro
• Nkarta
• Noile-Immune Biotech
• Notch Therapeutics
• Novartis
• nSAGE
• NSF Engineering Research Center for Cell Manufacturing Technologies
• Nurix Therapeutics
• Obsidian Therapeutics
• Oncodesign Biotechnology
• Oncora Medical
• OncoTracker
• Oncternal Therapeutics
• OnCyte
• Ono Pharmaceutical
• Opus Bio
• OrbiMed Advisors
• Osage University Partners
• Ospedale Pediatrico Bambino Gesù (OPBG)
• Otsuka Pharmaceutical
• Outpace Bio
• Overland Pharmaceuticals
• Oxford Biomedica
• Oxford BioTherapeutics
• Oxford MEStar
• PACT Pharma
• PanCELLa
• Parker Institute for Cancer Immunotherapy
• PersonGen BioTherapeutics
• Pfenex
• Pfizer
• PharmaCell
• PharmaEssentia
• Phio Pharmaceuticals
• PhoreMost
• Pieris Pharmaceuticals
• Pierre Fabre
• PolyBioCept
• Pontifax
• Porton Biologics
• Poseida Therapeutics
• Precigen
• Precision BioSciences
• Pregenen
• Progenitor Cell Therapy
• ProMab Biotechnologies
• Prometheus
• Prometheus Laboratories
• PureTech Health
• Qiagen
• Qilu Hospital of Shandong University
• RA Capital Management
• Redmile Group
• RedoxTherapeis
• Refuge Biotechnologies
• Regeneron Pharmaceutical
• Resilience
• resTORbio
• Roche
• Rockland Immunochemicals
• Roswell Park Cancer Institute
• RXi Pharmaceuticals
• Sana Biotechnology
• Sangamo Therapeutics
• Sanofi
• Scilifelab
• Scotia Biologics
• Seattle Children’s Research Institute
• Seattle Genetics
• Second Affiliated Hospital of Guangzhou Medical University
• Second Affiliated Hospital of Soochow University
• Selexis
• Servier
• Shangai Cancer Institute
• Shanghai 10th People's Hospital
• Shanghai Chest Hospital
• Shanghai East Hospital
• Shanghai Gencells Therapeutics
• Shanghai General Hospital
• Shanghai Jiao Tong University
• Shanghai OriginCell Therapeutics
• Shanghai UniCAR-Therapy Bio-Medicine Technology
• Sheba Medical Center
• Shoreline Biosciences
• Sidney Kimmel Comprehensive Cancer Center
• Sinobioway Cell Therapy
• Sistema and Russian Direct Investment Fund
• Sorrento Therapeutics
• SpringWorks Therapeutics
• St. Jude Children's Research Hospital
• Stage Cell Therapeutics
• Stand Up To Cancer
• Stanford University
• Stratophase
• Structured Immunity
• Sun Yat-sen University
• Syracuse Biopharma
• Takara Bio
• Takeda Pharmaceutical
• TC BioPharm
• T-Cell Factory
• TCR2 Therapeutics
• TCRCure Biopharma
• TCRyption
• T-Cure Bioscience
• Tel Aviv Sourasky Medical Center
• Temasek
• Teneobio
• Terumo BCT
• Tessa Therapeutics
• The Japanese Society for Regenerative Medicine
• The Netherlands Cancer Institute
• The Ohio State University
• Thermo Fisher Scientific
• Tianjin Medical University
• TILT Biotherapeutics
• Tiziana Life Sciences
• Tmunity Therapeutics
• Tongji Hospital
• Torque Therapeutics
• TrakCel
• Transgene
• Tscan Therapeutics
• Turnstone Biologics
• Twist Bioscience
• TxCell
• UNC Lineberger Comprehensive Cancer Center
• Universal Cells
• University College London
• University Health Network
• University Hospital Basel
• University Medicine Berlin
• University of Birmingham
• University of California
• University of Lausanne
• University of Manchester
• University of Milano-Bicocca
• University of Minnesota
• University of Montreal
• University of Munich
• University of Pennsylvania
• University of Pittsburgh
• University of South Australia
• University of Texas
• University of Tokyo Hospital
• Unum Therapeutics (renamed to Cogent Biosciences)
• Vaud University Hospital Center
• venBio
• Vertex Pharmaceuticals
• Vineti
• ViroMed
• Vitruvian Networks
• Vivo Capital
• Vor Biopharma
• Washington University
• Weill Cornell Medical College
• WindMIL Therapeutics
• Woodford Investment Management
• Wugen
• WuXi AppTec
• X-Body
• Xiangxue Life Sciences
• Xiangxue Pharmaceutical
• Yale University
• Yamaguchi University
• Zelluna Immunotherapy
• Zhejiang Huahai Pharmaceutical
• Zhejiang University
• ZIOPHARM Oncology

Methodology